Breaking News Instant updates and real-time market news.

DVAX

Dynavax

$10.82

0.05 (0.46%)

, MRK

Merck

$62.77

0.11 (0.18%)

17:24
10/09/16
10/09
17:24
10/09/16
17:24

Dynavax reports Phase 1/2 data on SD-101

Dynavax Technologies (DVAX) announced the first presentation of findings from an ongoing Phase 1/2 study evaluating SD-101 in combination with Keytruda, Merck's (MRK) anti-PD-1 treatment. Early results evaluating five patients with metastatic melanoma for efficacy and 16 patients for safety were reported. In patients naive to anti-PD-1 treatment objective responses were observed in three out of four, including one complete response and two partial responses. One patient with progressive disease while receiving anti-PD-1 therapy was observed to have stable disease. SD-101 in combination with pembrolizumab was well-tolerated. No dose-limiting toxicities of the combination were observed in any dose cohort, and a maximum tolerated dose was not identified. No immune-related adverse events were reported, and the most common treatment-emergent adverse events were grade 1-2 flu-like symptoms, including fever, chills and myalgia consistent with the engagement of TLR9 and production of interferon alpha. The study also included biomarker assessments suggesting that treatment with SD-101 and pembrolizumab resulted in elevation of gene signatures consistent with an increase in immune cell types and multiple immune functions.

DVAX

Dynavax

$10.82

0.05 (0.46%)

MRK

Merck

$62.77

0.11 (0.18%)

  • 25

    Oct

  • 06

    Nov

  • 16

    Nov

  • 15

    Dec

DVAX Dynavax
$10.82

0.05 (0.46%)

04/27/16
COWN
04/27/16
NO CHANGE
Target $60
COWN
Outperform
Dynavax PDUFA extension will not impact approval chances, says Cowen
Cowen analyst Phil Nadeau does not beleive Dynavax's Heplisav PDUFA extension by 3 months will impact chances of approval. The analyst suspects that the PDUFA change has more to do with FDA managing its workload than any reflection on the substance of the BLA, since both the FDA and Dynavax had agreed upon the original format of the BLA resubmission. Nadeau continues to rate Dynavax an Outperform and top small cap pick with a $60 price target on shares.
04/27/16
RBCM
04/27/16
DOWNGRADE
RBCM
Sector Perform
Dynavax downgraded to Sector Perform from Outperform at RBC Capital
04/28/16
RBCM
04/28/16
DOWNGRADE
RBCM
Sector Perform
Dynavax downgraded on drug safety concerns at RBC Capital
As noted earlier, RBC Capital downgraded Dynavax to Sector Perform from Outperform, The firm cited concerns about the safety of the company's Heplisav-B drug as the reason for its downgrade. RBC says that the FDA's decision to request individual trial data instead of the integrated dataset shows that the agency's scrutiny of the drug's safety has increased. Target to $17 from $48.
09/06/16
WBLR
09/06/16
NO CHANGE
WBLR
Outperform
FDA panel cancelation positive for Dynavax, says William Blair
William Blair analyst Y. Katherine Xu views the FDA's decision to canceled the November 16 Vaccines and Related Biological Products Advisory Committee meeting for Heplisav as a net positive for Dynavax. The agency's decision to move straight to the PDUFA date suggests that the Heplisav package is "sufficiently strong and adequate to warrant approval in the absence of a panel," Xu tells investors in a research note. She keeps an Outperform rating on Dynavax. The stock is up 19% to $13.00 in pre-market trading.
MRK Merck
$62.77

0.11 (0.18%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.

TODAY'S FREE FLY STORIES

AMAT

Applied Materials

$47.15

-0.13 (-0.27%)

07:50
09/22/17
09/22
07:50
09/22/17
07:50
Conference/Events
Applied Materials to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

07:50
09/22/17
09/22
07:50
09/22/17
07:50
General news
Fedspeak returned from the blackout period »

Fedspeak returned from…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:49
09/22/17
09/22
07:49
09/22/17
07:49
Hot Stocks
Phillips 66 Partners to sell $750M of Series A preferred units »

Phillips 66 Partners LP…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:48
09/22/17
09/22
07:48
09/22/17
07:48
Hot Stocks
Phillips 66 Partners announces $2.4B acquisition of interests from Phillips 66 »

Phillips 66 Partners…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSAR

Versartis

$21.60

-0.25 (-1.14%)

07:48
09/22/17
09/22
07:48
09/22/17
07:48
Recommendations
Versartis analyst commentary  »

Cantor still sees 55%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXEL

Exelixis

07:48
09/22/17
09/22
07:48
09/22/17
07:48
Downgrade
Exelixis rating change  »

Exelixis downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

07:48
09/22/17
09/22
07:48
09/22/17
07:48
Hot Stocks
Breaking Hot Stocks news story on Phillips 66 Partners »

Phillips 66 Partners to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:47
09/22/17
09/22
07:47
09/22/17
07:47
Hot Stocks
Breaking Hot Stocks news story on Phillips 66 Partners, Phillips 66 »

Phillips 66 Partners to…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

X

U.S. Steel

$24.66

-1.13 (-4.38%)

07:47
09/22/17
09/22
07:47
09/22/17
07:47
Technical Analysis
Technical View: U.S. Steel falls in early trading, analyst action »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:47
09/22/17
09/22
07:47
09/22/17
07:47
Hot Stocks
Breaking Hot Stocks news story on Phillips 66 Partners, Phillips 66 »

Phillips 66 Partners to…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:47
09/22/17
09/22
07:47
09/22/17
07:47
Hot Stocks
Breaking Hot Stocks news story on Phillips 66 Partners, Phillips 66 »

Phillips 66 Partners to…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBH

Zimmer Biomet

$113.06

-2.92 (-2.52%)

07:45
09/22/17
09/22
07:45
09/22/17
07:45
Recommendations
Zimmer Biomet analyst commentary  »

Value investors should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:45
09/22/17
09/22
07:45
09/22/17
07:45
General news
N.Y. FX Outlook »

N.Y. FX Outlook: The…

BABA

Alibaba

$177.39

-0.56 (-0.31%)

, TCEHY

Tencent

$44.15

-0.15 (-0.34%)

07:44
09/22/17
09/22
07:44
09/22/17
07:44
Periodicals
Alibaba, Tencent look towards emerging markets in mobile-payments race, WSJ says »

Chinese companies Alibaba…

BABA

Alibaba

$177.39

-0.56 (-0.31%)

TCEHY

Tencent

$44.15

-0.15 (-0.34%)

AAPL

Apple

$153.39

-2.68 (-1.72%)

GOOG

Alphabet

$932.45

0.87 (0.09%)

GOOGL

Alphabet Class A

$947.55

0.01 (0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

  • 29

    Nov

SPR

Spirit AeroSystems

$78.90

0.76 (0.97%)

07:44
09/22/17
09/22
07:44
09/22/17
07:44
Conference/Events
Spirit AeroSystems to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

AERI

Aerie Pharmaceuticals

$51.45

-1.95 (-3.65%)

07:44
09/22/17
09/22
07:44
09/22/17
07:44
Recommendations
Aerie Pharmaceuticals analyst commentary  »

Aerie pullback on AdComm…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 28

    Feb

CSCO

Cisco

$32.70

0.1 (0.31%)

07:44
09/22/17
09/22
07:44
09/22/17
07:44
Conference/Events
Cisco management to meet with Deutsche Bank »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

EFX

Equifax

$98.25

2.25 (2.34%)

07:41
09/22/17
09/22
07:41
09/22/17
07:41
Technical Analysis
Technical View: Equifax trades higher, analyst action »

Shares are back well…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AA

Alcoa

$46.25

-1.25 (-2.63%)

07:41
09/22/17
09/22
07:41
09/22/17
07:41
Downgrade
Alcoa rating change  »

Alcoa downgraded to Hold,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMX

CarMax

$68.84

0.17 (0.25%)

07:40
09/22/17
09/22
07:40
09/22/17
07:40
Earnings
CarMax reports Q2 EPS 98c, consensus 95c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

SYK

Stryker

$140.67

-2.04 (-1.43%)

, ZBH

Zimmer Biomet

$113.06

-2.92 (-2.52%)

07:40
09/22/17
09/22
07:40
09/22/17
07:40
Recommendations
Stryker, Zimmer Biomet analyst commentary  »

Growth investors should…

SYK

Stryker

$140.67

-2.04 (-1.43%)

ZBH

Zimmer Biomet

$113.06

-2.92 (-2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

SAVE

Spirit Airlines

$34.01

1.31 (4.01%)

07:39
09/22/17
09/22
07:39
09/22/17
07:39
Conference/Events
Spirit Airlines to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

IBM

IBM

$145.26

-0.62 (-0.43%)

, WBA

Walgreens Boots Alliance

$78.20

-0.64 (-0.81%)

07:39
09/22/17
09/22
07:39
09/22/17
07:39
Hot Stocks
IBM announces new agreement with Walgreens to deploy IBM retail analytics »

IBM (IBM) announced a new…

IBM

IBM

$145.26

-0.62 (-0.43%)

WBA

Walgreens Boots Alliance

$78.20

-0.64 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 23

    Sep

  • 22

    Oct

  • 25

    Oct

  • 15

    Nov

07:38
09/22/17
09/22
07:38
09/22/17
07:38
Conference/Events
Federal Reserve Bank of Dallas President participates in a conference »

Dallas Federal Reserve…

07:37
09/22/17
09/22
07:37
09/22/17
07:37
Conference/Events
Federal Reserve Bank of Kansas City President to speak at conference »

Kansas City Federal…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.